Dec 24, 2025 • MarketBeat
SOMEWHAT-BULLISH
Surgery Partners, Inc. (NASDAQ:SGRY) Given Average Recommendation of "Moderate Buy" by Brokerages
Surgery Partners, Inc. (NASDAQ:SGRY) has received a consensus "Moderate Buy" rating from ten brokerages, with an average 12-month price target of $27.11, despite some recent price target reductions by firms like Benchmark, Barclays, JPMorgan, and UBS. The company recently missed Q3 EPS and revenue estimates, reporting a negative net margin of 5.21% but 6.6% year-over-year revenue growth. SGRY shares opened at $15.53, trading below its 50-day and 200-day moving averages, and analysts project $0.67 EPS for the current year.
Dec 22, 2025 • Insider Monkey
NEUTRAL
Mizuho Securities Reaffirm Bullish Stance on Surgery Partners (SGRY)
Mizuho Securities reaffirmed its Buy rating on Surgery Partners (SGRY) with a $19 price target, citing a positive 2026 forecast for managed care and health facilities. Analyst Ann Hynes expects improved margins due to a commercial turnaround, particularly in Medicaid and Medicare. The stock has a consensus target price of $26.30 from 11 analysts, offering an estimated 67.5% upside potential.
Dec 22, 2025 • Yahoo Finance
BULLISH
Mizuho Securities Reaffirm Bullish Stance on Surgery Partners (SGRY)
Mizuho Securities analyst Ann Hynes has reiterated a Buy rating on Surgery Partners (SGRY) with a price target implying a 21% upside. This bullish outlook is driven by a positive 2026 forecast for the managed care and health facilities sector, anticipating improved margins in Medicaid and Medicare. The company, which provides surgical and ancillary services, has received Buy ratings from 8 out of 11 analysts, with a consensus target price of $26.30 indicating significant upside potential.
Dec 22, 2025 • Finviz
BULLISH
Mizuho Securities Reaffirm Bullish Stance on Surgery Partners (SGRY)
Mizuho Securities analyst Ann Hynes has reiterated a Buy rating for Surgery Partners (SGRY), setting a price target of $19, indicating a 21% upside. The bullish outlook is based on a positive 2026 forecast for managed care and health facilities, with Hynes anticipating improved margins in the coming years, particularly in Medicaid and Medicare. The stock has received Buy ratings from eight out of eleven analysts, with a consensus target price of $26.30, suggesting an estimated 67.5% upside potential.
Dec 21, 2025 • FOX40 News
BEARISH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surgery Partners, Inc. - SGRY
Pomerantz LLP is investigating potential securities fraud claims against Surgery Partners, Inc. (NASDAQ: SGRY) following a significant drop in its stock price. This investigation stems from the company's lowered full-year revenue and adjusted EBITDA guidance for 2025, which it attributed to capital deployment delays, divestitures, and a cautious outlook on commercial payer mix and volume. Investors are encouraged to contact the law firm for information on joining the class action.
Dec 21, 2025 • MarketBeat
NEUTRAL
Squarepoint Ops LLC Cuts Stock Position in Surgery Partners, Inc. $SGRY
Squarepoint Ops LLC significantly reduced its stake in Surgery Partners (NASDAQ:SGRY) by 74.5% during Q2, selling 154,971 shares and retaining 53,066 shares valued at $1.18 million. Surgery Partners missed Q3 earnings and revenue estimates and reported a negative net margin, despite a 6.6% year-over-year revenue growth. Analysts maintain a "Moderate Buy" consensus with an average price target of $27.11, while the stock currently trades around $15.70.